Kura Oncology (NASDAQ:KURA) posted its earnings results on Monday. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.01, Morningstar.com reports.
KURA traded up $0.80 during midday trading on Tuesday, hitting $12.17. 5,545 shares of the company traded hands, compared to its average volume of 382,796. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.22 and a current ratio of 10.22. The stock has a market capitalization of $416.21 million, a P/E ratio of -7.90 and a beta of 4.39. Kura Oncology has a 52 week low of $10.20 and a 52 week high of $24.02.
KURA has been the topic of several research analyst reports. Zacks Investment Research cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. BidaskClub upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, September 29th. Cann initiated coverage on shares of Kura Oncology in a research note on Monday. They set a “buy” rating and a $35.00 target price on the stock. Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Monday, October 22nd. Finally, Oppenheimer upped their target price on shares of Kura Oncology from $27.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, July 9th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $27.67.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in shares of Kura Oncology during the 2nd quarter valued at about $2,412,000. Swiss National Bank purchased a new stake in shares of Kura Oncology during the 2nd quarter valued at about $768,000. Prosight Management LP purchased a new stake in shares of Kura Oncology during the 2nd quarter valued at about $5,240,000. Sio Capital Management LLC increased its position in shares of Kura Oncology by 27.4% during the 2nd quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock valued at $15,244,000 after purchasing an additional 180,193 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Kura Oncology by 25.5% during the 2nd quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after purchasing an additional 406,963 shares during the last quarter. Institutional investors and hedge funds own 77.28% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/06/kura-oncology-kura-announces-earnings-results-beats-estimates-by-0-01-eps.html.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.